Clinical Trials Logo

Filter by:
NCT ID: NCT05667506 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

Start date: February 7, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-center, phase Ib/II trial to evaluate the safety and efficacy of CNCT19 treatment in Children and Adolescent (pediatric) patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).

NCT ID: NCT05667428 Not yet recruiting - Clinical trials for Hematopoietic Stem Cell Transplantation

A Multicenter Open-label Clinical Study on the Prevention of Premature Ovarian Failure After HSCT

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

HSCT is an effective method to cure hematologic malignancies. However, the reproductive system is prone to be damaged during radiotherapy and chemotherapy before transplantation, leading to ovarian failure, followed by infertility and premature ovarian failure (POF), which seriously affect the long-term quality of life of patients. This clinical trial aimed to observe the effect of Gonadotropin-releasing hormone analogues (GnRHa) on ovarian function in women of reproductive age after HSCT, so as to provide clinical evidence for whether GnRHa should be used for the prevention of POF.

NCT ID: NCT05667415 Not yet recruiting - Clinical trials for Chemotherapy;Advanced Gastric Cancer;Cisplatin;Disulfiram

Treatment of Advance Gastric Cancer With Disulfiram

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Chemotherapy is generally needed for advanced gastric cancer, and cisplatin is the main chemotherapy drug. However, there are many adverse reactions, including bone marrow suppression, gastrointestinal reactions, renal toxicity and neurotoxicity. These adverse reactions can affect the comfort and compliance of patients during treatment. At present, it is necessary to reduce adverse reactions of cisplatin and increase the chemotherapy sensitivity of gastric cancer to cisplatin. Recent studies have found that disulfiram has a potential anti-tumor effect. The disulfiram has shown significant in vivo and in vitro anti-tumor activity in preclinical studies, and has become a potential candidate drug for tumor treatment as an adjuvant in various clinical trials. In this clinical study, cisplatin combined with disulfiram is mainly used to treat advanced gastric cancer.

NCT ID: NCT05667402 Not yet recruiting - Clinical trials for Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Study of TBF Regimen in Allo-HSCT in Patients With CNS Leukemia

Start date: January 15, 2023
Phase: N/A
Study type: Interventional

Central nervous system (CNS) leukemia is a poor prognostic factor for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Thiotepa can penetrate the blood-brain barrier and has immunosuppressive effects and similar effects to irradiation in allo-HSCT. This project aims to investigate whether the TBF regimen is superior to the traditional modified BuCY2 regimen to improve the long-term survival of the CNS leukemia patients.

NCT ID: NCT05667363 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Digital Therapeutics on Inhalation Medication Adherence in COPD

Start date: December 20, 2022
Phase: N/A
Study type: Interventional

Digital Therapeutics (DTx) is an evidence-based,clinically evaluated software to treat,manage,and prevent a broad spectrum of diseases and disorders according to Digital Therapeutics Alliance,which may improve the adherence of patients with chronic obstructive pulmonary disease (COPD) to use inhaled medication and reduce the risk of acute exacerbation. This study plans to carry out a randomized controlled trial (RCT), using digital therapy to record and manage the behavior data of patients with COPD in the process of using inhaler medication, and analyze the correlation between digital therapy of COPD and patients' drug compliance and treatment effect.

NCT ID: NCT05667350 Recruiting - Clinical trials for Biliary Tract Cancer

AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC)

Start date: February 28, 2022
Phase:
Study type: Observational

ASCEND-BTC is a prospective, multi-center, observational study aimed at detecting early biliary tract cancer by combined assays of serum protein and cell-free DNA (cfDNA) methylation. The study will enroll approximately 492 participants diagnosed with biliary tract cancer and benign diseases.

NCT ID: NCT05667285 Enrolling by invitation - Clinical trials for Native Coronary Artery Stenosis

BIOFLOW-china Post-marketing Study (BIOTRONIK)

Start date: May 26, 2023
Phase:
Study type: Observational

This trial uses prospective, retrospective, observational, non-blinded, multi-center, single-arm, post-marketing hospital data collection and research methods. The goal of this study is to assess the safety of BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System in the Chinese patient population after marketing in China.

NCT ID: NCT05667272 Recruiting - Clinical trials for Postoperative Pancreatic Fistula

A Study on the Occurrence Time of Grade-B Pancreatic Fistula After Pancreatoduodenectomy

Start date: February 1, 2023
Phase:
Study type: Observational

To confirm the time point of CR-POPF of grade-B that patients with biochemical leak after PD or LPD turned into.

NCT ID: NCT05667220 Recruiting - Type 2 Diabetes Clinical Trials

Sitagliptin in Combination With Beidougen Capsule for Type 2 Diabetes

Start date: December 1, 2022
Phase: Phase 4
Study type: Interventional

The study was an interventional non-randomized controlled study and was divided into a Sitagliptin monotherapy (100 mg Qd) group and a Sitagliptin (100mg Qd)+Beidougen capsule (60mg Tid) combination treatment group for one week.

NCT ID: NCT05667194 Recruiting - Clinical trials for Advanced Solid Tumors

Phase 1 Trial of KH617

Start date: December 26, 2022
Phase: Phase 1
Study type: Interventional

KH617 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Injection.